-- Shareholders of Hunter-Fleming hold 3.1% stake in Newron --
Milan, Italy – May 14, 2008 - Newron Pharmaceuticals S.p.A. (“Newron”, SWX:
NWRN), a research and development company focused on novel CNS and pain therapies,
today announced that it has completed the acquisition of Hunter-Fleming Ltd.,
a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative
and inflammatory disorders. As announced earlier, shareholders of
Hunter-Fleming now hold 3.1 % in Newron.
About Newron PharmaceuticalsNewron Pharmaceuticals S.p.A. ( ) is a biopharmaceutical company focused
on novel therapies for diseases of the Central Nervous System and pain. Newron is
undertaking phase III trials with safinamide for the treatment of ParkinsonParkinson’s disease (PD) in
conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop,
manufacture and commercialize the compound in PD, Alzheimer´s disease, and other therapeutic
applications. Newron recently reported excellent results for its compound ralfinamide
in patients with Nerve Compression and Entrapment conditions, where neuropathic low back
pain (NLBP) represents the most common indication and for which there are no approved
drugs. The company expects to commence a phase IIb/III in NLBP later in 2008. In May
2008, Newron closed the acquisition of Hunter-Fleming, a private UK bio-pharmaceutical
company developing new medicines to treat neurodegenerative and inflammatory disorders.
Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss
Exchange, trading symbol NWRN.
For more information, contact:
Media Investors and analysts
Italy
Luca Benatti - CEO
Phone: +39 02 6103 4 626
E-mail: pr@newron.com
UK/Global media
Julia Phillips
Financial Dynamics
Phone: +44 (0) 20 7269 7187
Switzerland
Martin Meier-Pfister
The Investor Relations Firm AG
Phone: +41 43 244 81 40
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.